MEDP

+ Watchlist + Portfolio

Medpace Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $612.64
52-Week Range: $373.00 – $677.90
Market Cap: $16.93B
P/E (TTM): 35.59
EPS (TTM): 17.04
Dividend Yield: —

Advanced Metrics

Price/Book: 39.01
PEG Ratio: 3.26
Return on Equity: 162.15%
Return on Assets: 20.10%
Gross Margin: 72.35%
Operating Margin: 20.76%
Profit Margin: 17.66%
Current Ratio: 0.73
Debt/Equity: 0.33
Total Debt: $144.11M
Free Cash Flow: $510.40M
Revenue Growth: 17.20%
Earnings Growth: 37.10%
Enterprise Value: $16.74B

MEDP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.46B	$1.89B	$2.11B	$2.53B
Cost of Revenue	$1.03B	$1.36B	$1.45B	$1.77B
Gross Profit	$432.44M	$524.50M	$656.30M	$760.62M
Selling, General & Admin	$131.40M	$161.35M	$180.18M	$197.56M
Operating Expenses	$153.74M	$187.68M	$209.44M	$225.68M
Operating Income	$278.70M	$336.82M	$446.87M	$534.93M
EBITDA	$301.04M	$363.15M	$476.12M	$563.06M
Pretax Income	$282.86M	$335.68M	$475.92M	$542.38M
Income Tax	$37.49M	$52.87M	$71.54M	$91.25M
Net Income	$245.37M	$282.81M	$404.39M	$451.12M
Diluted EPS	7.28	8.88	12.63	15.28
Diluted Shares	33.67M	31.84M	32.01M	29.53M

MEDP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.27M	$245.45M	$669.44M	$497.05M
Receivables	$253.40M	$298.40M	$296.44M	$402.08M
Current Assets	$333.96M	$593.83M	$1.03B	$989.62M
Total Assets	$1.35B	$1.66B	$2.10B	$1.98B
Current Liabilities	$803.47M	$925.13M	$1.10B	$1.34B
Total Debt	$188.87M	$142.12M	$126.23M	$113.64M
Total Liabilities	$966.11M	$1.10B	$1.28B	$1.52B
Retained Earnings	-$359.83M	-$221.65M	$8.17M	-$459.98M
Shareholders' Equity	$386.39M	$558.95M	$825.54M	$459.07M
Working Capital	-$469.51M	-$331.30M	-$75.32M	-$354.12M
Net Debt	$21.73M	—	—	—

MEDP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$388.05M	$433.37M	$608.82M	$713.22M
Capital Expenditure	-$36.88M	-$36.65M	-$36.55M	-$31.36M
Free Cash Flow	$351.17M	$396.73M	$572.27M	$681.87M
Depreciation & Amortisation	$22.34M	$26.33M	$29.25M	$28.12M
Stock-Based Compensation	$21.41M	$20.52M	$25.51M	$34.79M
Investing Cash Flow	-$38.74M	-$34.63M	-$28.31M	-$31.14M
Financing Cash Flow	-$775.77M	-$182.64M	-$154.01M	-$860.39M
Share Repurchases	-$847.85M	-$144.02M	-$169.87M	-$917.39M
Net Change in Cash	-$426.47M	$216.10M	$426.50M	-$178.31M

MEDP Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$603.31M	$659.90M	$708.45M	$706.60M	$707.33M
Cost of Revenue	$423.30M	$462.96M	$503.13M	$510.28M	$505.69M
Gross Profit	$180.01M	$196.94M	$205.32M	$196.33M	$201.64M
Selling, General & Admin	$46.66M	$48.08M	$44.92M	$47.92M	$48.10M
Operating Expenses	$53.68M	$55.13M	$52.05M	$54.82M	$54.81M
Operating Income	$126.33M	$141.81M	$153.27M	$141.50M	$146.82M
EBITDA	$133.35M	$148.86M	$160.40M	$148.41M	$153.53M
Pretax Income	$124.54M	$142.84M	$156.83M	$147.59M	$151.66M
Income Tax	$34.28M	$31.70M	$21.70M	$23.72M	$30.30M
Net Income	$90.26M	$111.14M	$135.13M	$123.87M	$121.36M
Diluted EPS	3.10	3.86	4.67	4.28	4.25
Diluted Shares	29.14M	28.82M	28.96M	28.96M	28.55M

MEDP Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$46.33M	$285.35M	$497.05M	$652.68M	$502.69M
Receivables	$377.92M	$373.03M	$402.08M	$394.58M	$441.80M
Current Assets	$520.80M	$737.28M	$989.62M	$1.14B	$1.05B
Total Assets	$1.57B	$1.75B	$1.98B	$2.13B	$2.06B
Current Liabilities	$1.22B	$1.28B	$1.34B	$1.35B	$1.44B
Total Debt	$124.95M	$119.07M	$113.64M	$122.26M	$120.10M
Total Liabilities	$1.40B	$1.46B	$1.52B	$1.53B	$1.62B
Retained Earnings	-$703.22M	-$596.24M	-$459.98M	-$336.11M	-$511.37M
Shareholders' Equity	$172.35M	$293.64M	$459.07M	$598.31M	$433.86M
Working Capital	-$699.64M	-$546.63M	-$354.12M	-$205.96M	-$385.14M

MEDP Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$148.53M	$246.21M	$192.65M	$151.79M	$162.01M
Capital Expenditure	-$6.11M	-$10.71M	-$4.54M	-$6.81M	-$23.91M
Free Cash Flow	$142.41M	$235.50M	$188.12M	$144.97M	$138.10M
Depreciation & Amortisation	$7.01M	$7.05M	$7.13M	$6.91M	$6.71M
Stock-Based Compensation	$5.95M	$6.32M	$5.62M	$4.92M	$4.35M
Investing Cash Flow	-$6.02M	-$10.66M	-$4.47M	-$6.75M	-$23.89M
Financing Cash Flow	-$540.56M	$3.41M	$22.73M	$12.67M	-$288.34M
Share Repurchases	-$540.91M	-$4.57M	$0.00	$0.00	-$294.76M
Net Change in Cash	-$398.06M	$238.96M	$210.91M	$157.71M	-$150.21M

Market Snapshot

About

Medpace Holdings, Inc. is a global contract research organization (CRO) providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company offers full-service clinical development support from Phase I through Phase IV, along with laboratory and imaging services.